Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Cancer
NCT02273375Phase 3Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Feb 2015
- Primary completion
- Jul 2025
- Countries
- 19
01
Overview
A Phase 3 trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by Canadian Cancer Trials Group. Started Feb 2015; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02273375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02273375.